ReviewWorld journal of gastrointestinal pharmacology and therapeutics2016
Local ablative treatments for hepatocellular carcinoma: An updated review.
Review in World journal of gastrointestinal pharmacology and therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 122 citations in OpenAlex.
- Pooled it
- NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.Journal of the National Comprehensive Cancer Network : JNCCN · 2017Guideline
- Overexpression of PLK1 Molecule Following Incomplete Thermal Ablation Promotes the Proliferation and Invasion of Residual Hepatocellular Carcinoma.Molecular biotechnology · 2025Article
- Optical imaging guidance in oncologic surgery and interventional oncology.Pharmacological research · 2025Review
- Microwave ablation for liver metastases from colorectal cancer: A comprehensive review of clinical efficacy and safety.World journal of gastrointestinal surgery · 2025Review
- Digestive cancers: mechanisms, therapeutics and management.Signal transduction and targeted therapy · 2025Review
- Clinical study on ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma.American journal of translational research · 2025Article
- Predicting Treatment Response to Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients using a Deep Learning-based Approach.Current medical imaging · 2025Article
- Body-Mounted MR-Conditional Robot for Minimally Invasive Liver Intervention.Annals of biomedical engineering · 2024Article
- Review
- A Post-International Gastrointestinal Cancers' Conference (IGICC) Position Statements.Journal of hepatocellular carcinoma · 2024Article
- Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes.Cancer reports (Hoboken, N.J.) · 2023Review
- Long-term outcomes of combined radiofrequency ablation and multipronged ethanol ablation for the treatment of unfavorable hepatocellular carcinomaDiagnostic and interventional radiology (Ankara, Turkey) · 2023Article
- Comparison of NK cell subsets, receptors and functions induced by radiofrequency ablation and microwave ablation in HBV-associated primary hepatocellular carcinoma.Frontiers in oncology · 2023Article
- Indian College of Radiology and Imaging Guidelines on Interventions in Hepatocellular Carcinoma.The Indian journal of radiology & imaging · 2022Review
- Prediction Model for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Primary Hepatocellular Carcinoma 2 cm or Smaller.Digestive diseases and sciences · 2022Article
- Overall Survival of Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation (RFA) Treatment: a Retrospective Cohort Study from Two Referral Hospitals in Indonesia.Journal of gastrointestinal cancer · 2022Article
- Improving Adjuvant Liver-Directed Treatment Recommendations for Unresectable Hepatocellular Carcinoma: An Artificial Intelligence-Based Decision-Making Tool.JCO clinical cancer informatics · 2022Observational
- Review
- Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances.Journal of nanobiotechnology · 2022Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ablative treatments currently represent the first-line option for the treatment of early stage unresectable hepatocellular carcinoma (HCC). Furthermore, they are effective as bridging/downstaging therapies before orthotopic liver transplantation. Contraindications based on size, number, and location of nodules are quite variable in literature and strictly dependent on local expertise. Among ablative therapies, radiofrequency ablation (RFA) has gained a pivotal role due to its efficacy, with a reported 5-year survival rate of 40%-70%, and safety. Although survival outcomes are similar to percutaneous ethanol injection, the lower local recurrence rate stands for a wider application of RFA in hepato-oncology. Moreover, RFA seems to be even more cost-effective than liver resection for very early HCC (single nodule ≤ 2 cm) and in the presence of two or three nodules ≤ 3 cm. There is increasing evidence that combining RFA to transarterial chemoembolization may increase the therapeutic benefit in larger HCCs without increasing the major complication rate, but more robust prospective data is still needed to validate these pivotal findings. Among other thermal treatments, microwave ablation (MWA) uses high frequency electromagnetic energy to induce tissue death
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.